Apple might have to stop selling Apple Watch Series 9 in US due to health-related patent issue

We have confirmed reports that Apple will have to stop selling the Apple Watch Series 9 in the US due to a patent-related issue with a medical firm named Masimo. Apple has halted the sales and reportedly, “The move goes into effect through the online Apple Store at 3 P.M. this Thursday (December 21), with retail locations ceasing sales December 24 — just ahead of the holiday. The 24th is also the last day for pickup and delivery of online orders”.

Apple confirmed this in a statement to TechCrunch revealing that “A Presidential Review Period is in progress regarding an order from the U.S. International Trade Commission on a technical intellectual property dispute pertaining to Apple Watch devices containing the Blood Oxygen feature. While the review period will not end until December 25, Apple is preemptively taking steps to comply should the ruling stand. This includes pausing sales of Apple Watch Series 9 and Apple Watch Ultra 2 from Apple.com starting December 21, and from Apple retail locations after December 24.

Apple’s teams work tirelessly to create products and services that empower users with industry-leading health, wellness, and safety features. Apple strongly disagrees with the order and is pursuing a range of legal and technical options to ensure that Apple Watch is available to customers. Should the order stand, Apple will continue to take all measures to return Apple Watch Series 9 and Apple Watch Ultra 2 to customers in the U.S. as soon as possible”.

Apple also said that “Masimo has wrongly attempted to use the ITC to keep a potentially lifesaving product from millions of U.S. consumers while making way for their own watch that copies Apple.” Masimo says that Apple “began hiring Masimo employees, starting with Masimo’s Chief Medical Officer. In the Fall of 2020, Apple introduced the Series 6, manufactured in Asia.” and alleges that the company used its employees to include the technology in their own devices which is a theft. It is worth noting that the primary issue between Apple and Masimo is regarding “pulse oximetry, which utilizes an optical sensor to detect blood flow. Last month Masimo received FDA clearance to use its own wrist-worn product for prescription and over-the-counter use”.

Comments

  • No comments yet.
  • Add a comment

    Join our Mailing list!

    Get all latest news, exclusive deals and updates.